0001553350-24-000039.txt : 20240522 0001553350-24-000039.hdr.sgml : 20240522 20240522160528 ACCESSION NUMBER: 0001553350-24-000039 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240522 DATE AS OF CHANGE: 20240522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncology Institute, Inc. CENTRAL INDEX KEY: 0001799191 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 843562323 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39248 FILM NUMBER: 24973232 BUSINESS ADDRESS: STREET 1: 18000 STUDEBAKER RD STREET 2: SUITE 800 CITY: CERRITOS STATE: CA ZIP: 90703 BUSINESS PHONE: 562-735-3226 MAIL ADDRESS: STREET 1: 18000 STUDEBAKER RD STREET 2: SUITE 800 CITY: CERRITOS STATE: CA ZIP: 90703 FORMER COMPANY: FORMER CONFORMED NAME: DFP HEALTHCARE ACQUISITIONS CORP. DATE OF NAME CHANGE: 20200108 10-K/A 1 toi_10ka.htm
true 2023 FY 0001799191 0001799191 2023-01-01 2023-12-31 0001799191 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001799191 TOI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember 2023-01-01 2023-12-31 0001799191 2023-06-30 0001799191 2024-04-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K/A

(Amendment No. 2)

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 001-39248

The Oncology Institute, Inc.

(Exact name of registrant as specified in its charter)

Delaware   84-3562323
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
   

18000 Studebaker Rd, Suite 800

Cerritos, California

     90703
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant's telephone number, including area code: (562) 735-3226

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value per share TOI The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share TOIIW The Nasdaq Stock Market LLC

Securities registered pursuant to section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  ☐    No  ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  ☐    No  ☒

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒    No  ☐ 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  ☒    No  ☐ 

 
 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer   ☒ Smaller reporting company ☒
    Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes  ☐    No  ☒

The aggregate market value of voting stock held by non-affiliates of the Registrant, based on the closing price of $0.55 per shares of the Registrant’s common stock as reported by the Nasdaq Capital Market as of June 30, 2023, was approximately $41.6 million.

The registrant had outstanding 74,313,404 shares of common stock as of April 19, 2024.

DOCUMENTS INCORPORATED BY REFERENCE

None.

Audit Firm Id   Auditor Name   Auditor Location
243   BDO USA, P.C.   Costa Mesa, California

 
 

 

 

EXPLANATORY NOTE TO AMENDMENT NO. 2

 

This Amendment No. 2 on Form 10-K/A (this “Amendment”) further amends the Annual Report on Form 10-K for the year ended December 31, 2023 of The Oncology Institute, Inc. (the “Company”), which was initially filed with the Securities and Exchange Commission on March 28, 2024 (the “Original Filing”, and as amended by that certain first amendment to the Original Filing filed on April 22, 2024, the “Original Form 10-K”). This Amendment is being filed solely to amend the certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 appended as Exhibits 31.1 and 31.2 to the Original Form 10-K. These amended certifications include the introductory language of paragraph 4 and the language of paragraph 4(b) referring to internal control over financial reporting, which language was inadvertently omitted from the Company’s certifications in the Original Form 10-K. This Amendment does not alter or affect any other part or any other information originally set forth in the Original Form 10-K. This Amendment does not reflect events that have occurred subsequent to the filing of the Original Form 10-K or modify or update in any way disclosures made in the Original Form 10-K. Accordingly, this Amendment No. 2 should be read in conjunction with the Original Form 10-K and the Company’s other filings with the SEC.

 

3 
 

 

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules.

 

(a)Documents filed as part of the Annual Report on Form 10-K, as amended by this Amendment No. 2
(1)Financial Statements: See Index to Consolidated Financial Statements, which appears on Page 61 of the Original Form 10-K.
(2)Financial Statement Schedules: No financial statement schedules are included in the Original 10-K or this Amendment No. 2 as such schedules are not required or the information that would be included in such schedules is not material or is otherwise furnished.

(b)Exhibits: See Index to Exhibits below.
        Incorporated by Reference   Filed or Furnished Herewith
Exhibit Number   Description   Form   File Number   Exhibit   Filing Date    
31.1   Certification Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 of the Principal Executive Officer.                   X
31.2   Certification Pursuant to Rule 13a-14(a) under Securities Exchange Act of 1934 of the Principal Financial Officer.                   X
104   Cover Page Interactive Data File - (formatted as Inline XBRL and contained in Exhibit 101)                    

 

4 
 

 

 

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 2 to the Annual Report on Form 10-K/A to be signed on its behalf by the undersigned hereunto duly authorized, on May 22, 2024.

 

THE ONCOLOGY INSTITUTE, INC.
   
   
By: /s/ Mihir Shah
  Mihir Shah
 

Chief Financial Officer

(Principal Financial Officer and Duly Authorized Officer)

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons in the capacities held on the dates indicated.

 

 

Signature   Title   Date
*        
Daniel Virnich  

Chief Executive Officer

(Principal Executive Officer)

   May 22, 2024
/s/ Mihir Shah        
Mihir Shah  

Chief Financial Officer

(Principal Financial and Accounting Officer)

   May 22, 2024
*        
Richard Barasch   Director   May 22, 2024
*        
Karen Johnson   Director   May 22, 2024
*        
Mohit Kaushal   Director   May 22, 2024
*        
Gabriel Ling   Director   May 22, 2024
*        
Anne McGeorge   Director   May 22, 2024
*        
Maeve O’Meara   Director   May 22, 2024
*        
Mark Pacala   Director   May 22, 2024
*        
Brad Hively   Director   May 22, 2024

 

 

___________

* By Mihir Shah, as attorney-in-fact.

 

 

 

 

 EX-31.1 2 ex31x1.htm EXHIBIT 31.1

EXHIBIT 31.1

Certification of Chief Executive Officer

RULE 13a-14(a)/15d-14(a) CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

 

I, Daniel Virnich, certify that:

1. I have reviewed this Annual Report on Form 10-K for the period ended December 31, 2023 of The Oncology Institute, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:May 22, 2024

  /s/ Daniel Virnich  
 

Daniel Virnich

Chief Executive Officer

  

 

 EX-31.2 3 ex31x2.htm EXHIBIT 31.2

EXHIBIT 31.2

Certification of Chief Financial Officer

RULE 13a-14(a)/15d-14(a) CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Mihir Shah, certify that:

1. I have reviewed this Annual Report on Form 10-K for the period ended December 31, 2023 of The Oncology Institute, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:May 22, 2024

  /s/ Mihir Shah    
 

Mihir Shah

Chief Financial Officer

  

 

 

 EX-101.SCH 4 toi-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 toi-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 6 toi-20231231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Redeemable Warrants [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location EX-101.PRE 7 toi-20231231_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Apr. 19, 2024
Jun. 30, 2023
Document Type 10-K/A    
Amendment Flag true    
Amendment Description Amendment No. 2    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 001-39248    
Entity Registrant Name The Oncology Institute, Inc.    
Entity Central Index Key 0001799191    
Entity Tax Identification Number 84-3562323    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 18000 Studebaker Rd    
Entity Address, Address Line Two Suite 800    
Entity Address, City or Town Cerritos    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 90703    
City Area Code 562    
Local Phone Number 735-3226    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 41.6
Entity Common Stock, Shares Outstanding   74,313,404  
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 243    
Auditor Name BDO USA, P.C.    
Auditor Location Costa Mesa, California    
Common Stock [Member]      
Title of 12(b) Security Common Stock, $0.0001 par value per share    
Trading Symbol TOI    
Security Exchange Name NASDAQ    
Redeemable Warrants [Member]      
Title of 12(b) Security Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share    
Trading Symbol TOIIW    
Security Exchange Name NASDAQ    
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 5 40 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://theoncologyinstitute.com/role/Cover Cover Cover 1 false false All Reports Book All Reports toi-20231231.xsd toi-20231231_def.xml toi-20231231_lab.xml toi-20231231_pre.xml toi_10ka.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "toi_10ka.htm": { "nsprefix": "TOI", "nsuri": "http://theoncologyinstitute.com/20231231", "dts": { "schema": { "local": [ "toi-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "toi-20231231_def.xml" ] }, "labelLink": { "local": [ "toi-20231231_lab.xml" ] }, "presentationLink": { "local": [ "toi-20231231_pre.xml" ] }, "inline": { "local": [ "toi_10ka.htm" ] } }, "keyStandard": 40, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 5, "entityCount": 1, "segmentCount": 2, "elementCount": 70, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 43 }, "report": { "R1": { "role": "http://theoncologyinstitute.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "toi_10ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "toi_10ka.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r11", "r13", "r14", "r16" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r20" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r17" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r18" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "TOI_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://theoncologyinstitute.com/20231231", "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Redeemable Warrants [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://theoncologyinstitute.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r19" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r20": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001553350-24-000039-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001553350-24-000039-xbrl.zip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�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end XML 19 toi_10ka_htm.xml IDEA: XBRL DOCUMENT 0001799191 2023-01-01 2023-12-31 0001799191 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001799191 TOI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember 2023-01-01 2023-12-31 0001799191 2023-06-30 0001799191 2024-04-19 iso4217:USD shares iso4217:USD shares true 2023 FY 0001799191 10-K/A Amendment No. 2 true 2023-12-31 --12-31 false 001-39248 The Oncology Institute, Inc. DE 84-3562323 18000 Studebaker Rd Suite 800 Cerritos CA 90703 562 735-3226 Common Stock, $0.0001 par value per share TOI NASDAQ Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share TOIIW NASDAQ No No Yes Yes Non-accelerated Filer true true false false false false 41600000 74313404 243 BDO USA, P.C. Costa Mesa, California